Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics

Cancer Research

Volumn 75, Issue 2, 2015, Pages 296-305

  Crompton, Joseph G ^a,b,c   Sukumar, Madhusudhanan ^a   Roychoudhuri, Rahul ^a   Clever, David ^a,c   Gros, Alena ^a   Eil, Robert L ^a   Tran, Eric ^a   Hanada, Ken Ichi ^a   Yu, Zhiya ^a   Palmer, Douglas C ^a   Kerkar, Sid P ^a   Michalek, Ryan D ^d   Upham, Trevor ^a   Leonardi, Anthony ^a   Acquavella, Nicolas ^a,g   Wang, Ena ^e   Marincola, Francesco M ^e   Gattinoni, Luca ^a   Muranski, Pawel ^a   Sundrud, Mark S ^f   Klebanoff, Christopher A ^a   Rosenberg, Steven A ^a   Fearon, Douglas T ^c   Restifo, Nicholas P ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d METABOLON INC   (United States)

^e SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

^f SCRIPPS RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR;

ANIMAL EXPERIMENT; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL SURVIVAL; CELL THERAPY; CONTROLLED STUDY; ENZYME INHIBITION; FATTY ACID OXIDATION; HUMAN; HUMAN CELL; LYMPHOCYTE TRANSFER; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE; ADOPTIVE IMMUNOTHERAPY; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DRUG EFFECTS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; MELANOMA; MELANOMA, EXPERIMENTAL; NONOBESE DIABETIC MOUSE; PATHOLOGY; PROCEDURES; RANDOMIZATION; TRANSGENIC MOUSE; TUMOR CELL CULTURE;

ANIMALS; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, TRANSGENIC; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RANDOM ALLOCATION; TUMOR CELLS, CULTURED;

EID: 84921044688     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-2277     Document Type: Article

References (39)

1. Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 2006;90:1-50.
2. Stagg J, Johnstone RW, Smyth MJ. From cancer immunosurveillance to cancer immunotherapy. Immunol Rev 2007;220:82-101.
3. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011;17:4550-7.
4. Chodon T, Comin-Anduix B, Chmielowski B, Koya RC, Wu Z, Auerbach M, et al. Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res 2014;20:2457-65.
5. Klebanoff CA, Gattinoni L, Palmer DC, Muranski P, Ji Y, Hinrichs CS, et al. Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. Clin Cancer Res 2011;17:5343-52.
6. Baitsch L, Baumgaertner P, Devevre E, Raghav SK, Legat A, Barba L, et al. Exhaustion of tumor-speci fic CD8+ T cells in metastases from melanoma patients. J Clin Invest 2011;121:2350-60.
7. Araki K, Turner AP, Shaffer VO, Gangappa S, Keller SA, BachmannMF, et al. mTOR regulates memory CD8 T-cell differentiation. Nature 2009;460:108-12.
8. Kim EH, Sullivan JA, Plisch EH, Tejera MM, Jatzek A, Peskett E, et al. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. J Immunol 2012;188:4305-14.
9. Okkenhaug K, Bilancio A, Farjot G, Priddle H, Sancho S, Peskett E, et al. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 2002;297:1031-4.
10. Macintyre AN, Finlay D, Preston G, Sinclair LV, Waugh CM, Tamas P, et al. Protein kinase B controls transcriptional programs that direct cytotoxic T cell fate but is dispensable for T cell metabolism. Immunity 2011;34:224-36.
11. Powell JD, Delgoffe GM. The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism. Immunity 2010;33:301-11.
12. Kim EH, Suresh M. Role of PI3K/Akt signaling in memory CD8 T cell differentiation. Front Immunol 2013;4:20.
13. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012;149:274-93.
14. Finlay DK. mTORC1 regulates CD8+ T-cell glucose metabolism and function independently of PI3K and PKB. Biochem Soc Trans 2013;41:681-6.
15. + T cell survival is regulated differentially by protein kinase Ctheta, c-Rel, and protein kinase B. J Immunol 2007;178:2932-9.
16. Hand TW, Cui W, Jung YW, Sefik E, Joshi NS, Chandele A, et al. Differential effects of STAT5 and PI3K/AKT signaling on effector and memory CD8 Tcell survival. Proc Natl Acad Sci U S A 2010;107:16601-6.
17. Rathmell JC, Elstrom RL, Cinalli RM, Thompson CB. Activated Akt promotes increased resting T cell size, CD28-independent T cell growth, and development of autoimmunity and lymphoma. Eur J Immunol 2003;33:2223-32.
18. Calleja V, Laguerre M, Parker PJ, Larijani B. Role of a novel PH-kinase domain interface in PKB/Akt regulation: structural mechanism for allosteric inhibition. PLoS Biol 2009;7:e17.
19. Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA. Generation of tumor-in filtrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 2003;26:332-42.
20. Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 2003;198:569-80.
21. Ferrick DA, Neilson A, Beeson C. Advances in measuring cellular bioenergetics using extracellular flux. Drug Discov Today 2008;13:268-74.
22. Graef P, Buchholz VR, Stemberger C, Flossdorf M, Henkel L, Schiemann M, et al. Serial transfer of single-cell-derived immunocompetence reveals stemness of CD8(+) central memory T cells. Immunity 2014;41:116-26.
23. Klebanoff CA, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones AR, Finkelstein SE, et al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A 2005;102:9571-6.
24. Klebanoff CA, Gattinoni L, Restifo NP. CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev 2006;211:214-24.
25. Kaech SM, Cui W. Transcriptional control of effector and memory CD8+ T cell differentiation. Nat Rev Immunol 2012;12:749-61.
26. Sukumar M, Liu J, Ji Y, Subramanian M, Crompton JG, Yu Z, et al., Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. J Clin Invest 2013;123:4479-88.
27. Pearce EL, Walsh MC, Cejas PJ, Harms GM, Shen H, Wang LS, et al. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 2009;460:103-7.
28. Evans AM, DeHaven CD, Barrett T, Mitchell M, Milgram E. Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. Anal Chem 2009;81:6656-67.
29. van der Windt GJ, Everts B, Chang CH, Curtis JD, Freitas TC, Amiel E, et al. Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development. Immunity 2012;36:68-78.
30. Choi SW, Gerencser AA, Nicholls DG. Bioenergetic analysis of isolated cerebrocortical nerve terminals on a microgram scale: spare respiratory capacity and stochastic mitochondrial failure. J Neurochem 2009;109:1179-91.
31. Yadava N, Nicholls DG. Spare respiratory capacity rather than oxidative stress regulates glutamate excitotoxicity after partial respiratory inhibition of mitochondrial complex I with rotenone. J Neurosci 2007;27:7310-7.
32. van der Windt GJ, O'Sullivan D, Everts B, Huang SC, Buck MD, Curtis JD, et al.CD8 memory T cells have a bioenergetic advantage that underlies their rapid recall ability. Proc Natl Acad Sci U S A 2013;110:14336-41.
33. Gerencser AA, Neilson A, Choi SW, Edman U, Yadava N, Oh RJ, et al. Quantitative microplate-based respirometry with correction for oxygen diffusion. Anal Chem 2009;81:6868-78.
34. Nicholls DG, Darley-Usmar VM, Wu M, Jensen PB, Rogers GW, Ferrick DA. Bioenergetic profile experiment using C2C12 myoblast cells. J Vis Exp 2010;pii:2511.
35. + T cells is dictated by antigen exposure history and nature of the infection. Immunity 2011;34:781-93.
36. Fearon DT. The expansion and maintenance of antigen-selected CD8(+) T cell clones. Adv Immunol 2007;96:103-39.
37. Crompton JG, Sukumar M, Restifo NP. Uncoupling T-cell expansion from effector differentiation in cell-based immunotherapy. Immunol Rev 2014;257:264-76.
38. O'Sullivan D, van der Windt GJ, Huang SC, Curtis JD, Chang CH, Buck MD, et al. Memory CD8(+) T cells use cell-intrinsic lipolysis to support the metabolic programming necessary for development. Immunity 2014;41:75-88.
39. Finlay D, Cantrell DA. Metabolism, migration and memory in cytotoxic T cells. Nat Rev Immunol 2011;11:109-17.